NIHR’s Be Part of Research registry

NIHR’s Be Part of Research registry We would like to share this blog with you, from the NIHR Chief Executive Officer and DHSC Chief Scientific Adviser Professor Lucy Chappell, who reflects on the vital role of participants in health and care research and how the NIHR’s Be Part of Research registry will help transform the…

In Conversation with… Dr Patrick Harrington, discussing the new study on thrombosis risk in MPN patients using QRISK3 Score

The vlogcast features Dr Patrick Harrington, Consultant Haematologist, Guy’s & St Thomas’ Hospital, discussing the new study on thrombosis risk in MPN patients using QRISK3 Score.  Dr Harrington explains the research the team at Guy’s Hospital have done to see if a new way of assessing patients’ risk of thrombosis (clotting) called QRISK3, could be…

News release from Pharma& – MHRA approval of Pegasys for ET & PV patients

MHRA approves pharmaand GmbH’s Pegasys® (peginterferon alfa-2a) as a treatment for eligible patients with the myeloproliferative neoplasms (MPNs) blood cancers polycythaemia vera (PV) and essential thrombocythaemia (ET) First MHRA approval of an interferon alfa as a monotherapy treatment for adults with essential thrombocythaemia (ET) First MHRA approval of an interferon alfa as a monotherapy treatment…